Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) traded up 7.6% on Tuesday . The company traded as high as $16.34 and last traded at $16.34. 33,479 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 200,741 shares. The stock had previously closed at $15.19.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research note on Friday, September 20th.
Read Our Latest Analysis on Pulse Biosciences
Pulse Biosciences Price Performance
The business's 50 day simple moving average is $17.38 and its 200 day simple moving average is $14.44.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the previous year, the business earned ($0.19) earnings per share.
Institutional Investors Weigh In On Pulse Biosciences
Several hedge funds have recently added to or reduced their stakes in PLSE. BNP Paribas Financial Markets boosted its holdings in shares of Pulse Biosciences by 63.6% during the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company's stock worth $66,000 after buying an additional 2,952 shares during the period. Quest Partners LLC acquired a new position in shares of Pulse Biosciences in the second quarter valued at approximately $91,000. Price T Rowe Associates Inc. MD bought a new position in shares of Pulse Biosciences during the first quarter worth approximately $88,000. Cetera Advisors LLC acquired a new stake in Pulse Biosciences during the 1st quarter worth approximately $109,000. Finally, Creative Planning boosted its stake in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after purchasing an additional 11,667 shares during the period. Institutional investors and hedge funds own 76.95% of the company's stock.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
